PubMed Health⌕ Search

PubMed · 12508750

[Prostatic tumor: how many biopsies?].

Abstract

INTRODUCTION: Ultrasound-guided prostatic biopsy is usually performed by sextants according to Hodge, but the authors feel that 6 biopsies are insufficient. It has been suggested that the number of prostatic biopsies be increased and the mapped areas extended, but this causes discomfort to patients and increases effective costs. The authors suggest repetition of biopsies in "risk" cases, routinely selecting patients taking into account the best cost-benefit ratio. MATERIALS AND METHODS: From January 2000 to December 2001, 682 first series biopsies were performed on as many patients. A Stamey modified sextant technique was used: 6 biopsies, 3 on each side carried out more posterolaterally than the original technique. The biopsy procedure was repeated within 4 months in 11 patients with high risk clinical parameters (PSA > 10 or high PSA and prostatic nodule). During the period of observation, 25 patients had over 0.75 ng/year increase in their PSA and so biopsies were repeated. RESULTS: After the first biopsy series, 277 were positive. Of the 11 repeated biopsies, 3 were positive. Of the 25 patients with altered PSA velocity, 9 were positive. DISCUSSION AND CONCLUSIONS: It has been shown that only 10-12% of biopsies are false negative in the sextant biopsy series when taken posterolaterally. The techniques that increase the number of biopsies have around 3-5% false negatives, but this involves more discomfort for the patient, local anaesthesia and a possible increase in complications. The procedure whereby biopsies were only repeated in patients with high risk clinical elements, saved 3852 biopsies from being carried out, with an economic saving (just on the histological exam that was not carried out) assessed at 59.681,80 Euro (115,560,000 Lire) for our Local Health Service.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Andrea Fandella, GianLuca Drago-Ferrante, Luigi Faggiano, Luigino Maccatrozzo, Franco Merlo, Giuseppe Anselmo. 2002. [Prostatic tumor: how many biopsies?].. https://pubmed.ncbi.nlm.nih.gov/12508750/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Non-radical diagnostic biopsies do not negatively influence melanoma patient survival.

BACKGROUND: In fair-skinned Caucasian populations both the incidence and mortality rates of cutaneous melanoma have been increasing over the past decades. With adjuvant therapies still being under investigation, early detection is the only way to improve melanoma patient survival. The influence of incisional biopsies on melanoma patient survival has been discussed for many years. This study investigates both the influence of diagnostic biopsy type and the presence of residual tumor cells in the re-excision specimen on disease free and overall survival. METHODS: After (partial) removal of a pigmented skin lesion 471 patients were diagnosed with stage I/II melanoma and underwent re-excision and a sentinel node biopsy. All patients were followed prospectively, mean follow up >5 years. Patients were divided according to their diagnostic biopsy type (wide excision biopsy, narrow excision biopsy, excision biopsy with positive margins and incisional biopsy) and the presence of residual tumor cells in their re-excision specimen. Survival analysis was done using Cox's proportional hazard model adjusted for eight important confounders of melanoma patient survival. RESULTS: The diagnostic biopsy was wide in 279 patients, narrow in 109 patients, 52 patients underwent an excision biopsy with positive margins and 31 patients an incisional biopsy. In 41 patients residual tumor cells were present in the re-excision specimen. Both the diagnostic biopsy type and the presence of tumor cells in the re-excision specimen did not influence disease free and overall survival of melanoma patients. CONCLUSIONS: Non-radical diagnostic biopsies do not negatively influence melanoma patient survival.

Biopsy↗